Bone Metabolism After Bariatric Surgery

NCT01824797 | Completed

• 1 other identifier: Pro00044248
• Study Type: observational
• Target: 42
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose and objective of this study is to determine the changes in bone metabolism after bariatric surgery in postmenopausal women. This is a prospective cohort study that will enroll up to 40 postmenopausal female subjects with class II and III obesity from the Duke Center for Metabolic and Weight Loss Surgery. The study team will enroll subjects that are already being scheduled for either sleeve gastrectomy or Roux-en-Y gastric bypass. The osteoclast activity, the osteoblast activity, and the bone mineral density will be measured in all subjects preoperatively and 12 months postoperatively through research specific blood tests and Dual energy x-ray Absorptiometry (DEXA) scans. The primary endpoints are change in osteoclast activity as measured by C-terminal telopeptide of type I collagen and change in bone density as measured by DEXA scan. These are continuous variable and given the small sample size the investigators will use a nonparametric Wilcoxon rank-sum test to compare the difference in one year change in these variables. There is a slight risk of loss of confidentiality. Every effort will be made to protect all PHI. There is also the risk of increased exposure to radiation from the DEXA scans performed twice with each subjects participating in the study.

Conditions

Obesity; Osteoporosis

Keywords

Bone mineral density; sleeve gastrectomy; roux-en-y; postmenopausal females; bone loss

Outcome Measures

Primary Outcomes (1)

• Changes in Bone Mineral Density

  Changes in bone mineral density will be determined by comparing a peroperative DEXA scan with a one year postoperative DEXA scan on postmenopausal subjects who have already planned to undergo Roux-en-Y gastric bypass or sleeve gastrectomy.

  Baseline to one year postoperative

Secondary Outcomes (1)

• Biochemical Changes in Bone Metabolism

  Baseline to one year postoperative

Study Arms (2)

Roux-en-Y Gastric Bypass

Changes in bone mineral density will be determined by comparing a peroperative DEXA scan with a one year postoperative DEXA scan on postmenopausal subjects who have already planned to undergo Roux-en-Y gastric bypass or sleeve gastrectomy. Serum will be collected from subjects preoperatively and 12 months postoperatively. The serum will be used at the completion of the study to run enzyme-linked immunosorbent assay (ELISA) to determine biochemical changes in bone metabolism.

Sleeve Gastrectomy

Changes in bone mineral density will be determined by comparing a peroperative DEXA scan with a one year postoperative DEXA scan on postmenopausal subjects who have already planned to undergo Roux-en-Y gastric bypass or sleeve gastrectomy. Serum will be collected from subjects preoperatively and 12 months postoperatively. The serum will be used at the completion of the study to run enzyme-linked immunosorbent assay (ELISA) to determine biochemical changes in bone metabolism.

Eligibility Criteria

• Age: 40 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Postmenopausal females scheduled to undergo Roux-en-Y gastric bypass or Sleeve Gastrectomy.

You may qualify if:

• Postmenopausal women as determined by having a history of no menstrual bleed for greater than one year.
• Body Mass Index ≥35 kg/m² and stable weight for the previous 3 months.
• Able to speak and read English.
• Being scheduled for either Roux-en-Y gastric bypass or sleeve gastrectomy.

You may not qualify if:

• A documented history of osteoporosis or currently receiving medical treatment for osteoporosis with bisphosphonates, teriparatide, raloxifene, or denosumab.
• Weight greater than 295 pounds as this is the weight limit for our Dual-energy X-ray absorptiometry machine.
• Current or past (less than 1 year from enrollment) usage of estrogen hormone replacement therapy.
• Current smoker
• Any history of glucocorticoid use greater than one year in duration or current use of glucocorticoids.

Sponsors & Collaborators

• Duke University: lead
• Society of American Gastrointestinal and Endoscopic Surgeons: collaborator

Study Sites (1)

Duke Center for Metabolic and Weight Loss Surgery

Durham, North Carolina, 27704, United States

Location

Related Links

• Luhrs, A.R., Davalos, G., Lerebours, R. et al. Surg Endosc (2019)

Biospecimen

Retention: SAMPLES WITH DNA

Serum will be collected from the subjects preoperatively and 12 months postoperatively. The serum will be used at the completion of the study to run enzyme-linked immunosorbent assay (ELISA) to determine biochemical changes in their bone metabolism.

MeSH Terms

Conditions

Obesity; Osteoporosis; Bone Diseases, Metabolic

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Bone Diseases; Musculoskeletal Diseases; Metabolic Diseases

Study Officials

• Daniel Guerron, MD

  Duke University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 2, 2013
• First Posted: April 5, 2013
• Study Start: May 1, 2013
• Primary Completion: May 31, 2018
• Study Completion: May 31, 2018
• Last Updated: August 16, 2019

Record last verified: 2019-08

Locations

US (1)